Aclaris Therapeutics, Inc. (ACRS) EPS Estimated At $-0.96 as of March, 11

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Corporate Logo

Aclaris Therapeutics, Inc. (NASDAQ:ACRS)’s quarterly earnings will be reported on March, 11., Faxor reports. Analysts predict $-0.96 earnings per share, which is $0.16 down or 20.00 % from 2018’s $-0.8 earnings per share. Wall Street now forecasts -9.43 % EPS growth despite Aclaris Therapeutics, Inc. previous quarter’s EPS of $-1.06. Ticker’s shares touched $6.63 during the last trading session after 2.64% change.Aclaris Therapeutics, Inc. has volume of 310,567 shares. Since March 6, 2018 ACRS has declined 65.15% and is downtrending. The stock underperformed the S&P 500 by 69.52%.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology.The firm is worth $271.41 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor.Last it reported negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

For more Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news released recently go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments – GlobeNewswire” released on November 06, 2018, “Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada – GlobeNewswire” on April 06, 2018, “Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata – GlobeNewswire” with a publish date: June 28, 2018, “Aclaris Therapeutics Closes Acquisition of RHOFADEĀ® (oxymetazoline hydrochloride) cream, 1% from Allergan – GlobeNewswire” and the last “Aclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Underrepresented Minority Groups – GlobeNewswire” with publication date: October 01, 2018.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.